Hideaki Watanabe

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders

Kazuaki Chayama, Shoichi Takahashi, Joji Toyota et al. · Hepatology · 2011 · 335 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options

Yoshiyuki Suzuki, Kenji Ikeda, Fumitaka Suzuki et al. · Journal of Hepatology · 2012 · 236 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14

Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir

Yoshiyasu Karino, Joji Toyota, Kenji Ikeda et al. · Journal of Hepatology · 2012 · 166 citations

Life Sciences, Infectious Diseases, Pharmacotherapy +15

Asymmetric Catalysis on the Intramolecular Cyclopropanation of α-Diazo-β-keto Sulfones

Masahiro Honma, Takashi Sawada, Yuri Fujisawa et al. · Journal of the American Chemical Society · 2003 · 138 citations

Natural Sciences, Chemistry, Biocatalysis +14

Predictive Factors Associated With Acute Ocular Involvement in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

Chie Sotozono, Mayumi Ueta, Eiji Nakatani et al. · American Journal of Ophthalmology · 2015 · 136 citations

Medicine, Dermatology, Ophthalmology +9